Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $17
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.